ISAN CHEN - 14 Sep 2021 Form 3 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director
Signature
/s/ John Healy, Attorney-in Fact
Issuer symbol
TYRA
Transactions as of
14 Sep 2021
Net transactions value
$0
Form type
3
Filing time
14 Sep 2021, 21:20:40 UTC
Next filing
17 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TYRA Common Stock 131,339 14 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TYRA Series A Preferred Stock 14 Sep 2021 Common Stock 42,509 $0.000000 Direct F2
holding TYRA Series B Preferred Stock 14 Sep 2021 Common Stock 18,935 $0.000000 Direct F2
holding TYRA Stock Option (Right to Buy) 14 Sep 2021 Common Stock 67,467 $2.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 37,105 shares subject to repurchase by us, which are subject to vesting.
F2 The shares of Series A Preferred Stock and Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock and Series B Preferred Stock has no expiration date.
F3 1/36th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney